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ed a significant longer survival for patients with stable disease
after topotecan treatment compared to those with disease pro-
gression. Although in all studies topotecan therapy was well
tolerated by the patients, the percentage of grade 3 and 4
hematological toxicities is high. Other clinical complications
are rare, but dose reductions and treatment delays are re-
quired. In a study with a topotecan dosage of 1.25 mg/m2/day
published by Perez-Soler et al. [11], hematological toxicities
such as granolocytopenia and thrombocytopenia grade 4 were
observed in 28 and 11% of cycles, respectively. 
As it became apparent by the analysis of Armstrong and
O`Reilly [12] that the hematological toxicities are highest dur-
ing the 1st cycle, the SOABB study group conducted a phase
II study with an initial topotecan dose of 1.25 mg/m2/day to re-
duce the hematological toxicities. In the following cycles the
doses were increased or decreased depending on toxicities by
a standard operational procedure.
Primary interest of this phase II study was median survival
time of the patients, other objectives were the evaluation of
the response rate and response duration of topotecan
monotherapy in the second-line therapy of SCLC after plat-
inum-based or non-platinum-based first-line therapy. The as-
sessment of hematologic and non-hematologic toxicities and
the assessment of the dose intensity were further objectives.
Patients and Methods
Eligibility Criteria
All patients were required to have a histologically or cytologically con-
firmed diagnosis of SCLC. They had to have first-line therapy and were
categorized according to a platinum-based or non-platinum containing
first-line therapy. At least one tumor lesion had to be measurable two-di-
mensionally. Other eligibility criteria included an Eastern Cooperative
Oncology Group (ECOG) performance status of less than or equal to 2,
Introduction
Small-cell lung cancer (SCLC) accounts for about 25% of lung
cancer at initial diagnosis. It is a highly chemosensitive disease,
but despite high initial response rates, the median survival
time is only 9–16 months in limited disease and 6–12 months
in extensive disease [1, 2]. About 70% of the patients who
have limited disease and over 90% of patients who have ex-
tensive disease will develop recurrent or progressive disease.
There is no standard second-line therapy following first-line
treatment, and the prognosis after relapse is poor [3]. CAV
(cyclophosphamide, doxorubicine, vincristine) is often used
after first-line treatment with etoposide and cisplatin. In two
studies, CAV produced second-line response rates of 13 and
28% [4, 5], but duration of response to second-line chemo-
therapy is short, with a median survival time of 10–20 weeks
[6].
Thus the identification of new, more active drugs is clearly
crucial. Among several new drugs investigated during the last
few years, topotecan has demonstrated significant activity. It is
a semi-synthetic, water-soluble derivative of the alkaloid
camptothecin, a specific inhibitor of the topoisomerase I. Inhi-
bition of this enzyme results in cell-killing DNA damage dur-
ing the course of DNA replication. It proves to be effective in
patients with brain metastases and it may be effective in pre-
venting brain metastases. 
Topotecan passes the intact blood-brain barrier, and two
phase II studies have already been performed in patients with
relapsed or refractory SCLC with topotecan as a single agent
at a dosage of 1.5 or 2 mg/m2/day on 5 consecutive days [7, 8].
In a phase III comparison, the monotherapy with topotecan
resulted in the same responses and survival as the combina-
tion of CAV, symptoms relief was significantly better with the
topotecan treatment [9]. Additionally, Lane et al. [10] report-
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corresponding to a Karnofsky index > 60%, a sufficient bone marrow and
renal function and for women with childbearing potential an adequate
contraception. All patients gave written informed consent before study
entry.
Patients were ineligible if they had a history of first-line therapy with any
topoisomerase I inhibitor, a history of other neoplasms than SCLC,
surgery within the last two weeks prior to inclusion, or a history of hyper-
sensitivity to topotecan. Also ineligible were pregnant or lactating women
and patients with severe infections.
Pretreatment and Follow-up Studies
At the beginning and at the end of the study, all patients underwent a
complete medical history. An assessment of performance status and stag-
ing were done at the beginning of the study, at the beginning of each cycle
and at the end of the study. Blood counts were done at the beginning and
at the end of the study, at the beginning of each cycle and during each
cycle at day 8 and 15; blood chemistry was obtained at the beginning and
the end of the study and at the beginning of each cycle.
Stratification
Patients were stratified in 2 groups based on first-line therapy, either fail-
ure after platinum-based chemotherapy or failure after non-platinum con-
taining chemotherapy.
Retrospective strata include patients with sensitive or refractory disease
as well as the duration of the remission of the first-line therapy.
Treatment Schedule
Topotecan was administered as a starting dose of 1.25 mg/m2/day for 5
consecutive days every 21 days. Patients could receive a maximum of 6 cy-
cles. Dose modifications were performed in steps by 0.25 mg/m2/day
based on hematological toxicity.
Grades of toxicity that occurred during the first treatment course will be
reviewed and the dose for the next treatment course will be escalated by
one step if only toxicities of NCIC CTCG grade 2 occurred.
The dose could be reduced in one of the following cases:
– NCIC CTCG grade 3 leukopenia (neutrophils 1.0 × 109/l) ≥ 7 days
– febrile neutropenia (T ≥ 38.2 °C and neutrophils < 0.5 and necessity of
antibiotics)
– NCIC CTCG grade 3 thrombocytopenia (thrombocytes < 25 × 109/l)
– neutrophils < 1.5 × 109/l and thrombocytes < 100 × 109/l on day 22
The lowest dose level was 1.0 mg/m2/day.
Re-escalation after dose reduction was not allowed.
Statistical Analysis
Data were analyzed by descriptive statistical methods.
Results
From March 1998 to January 1999 a total of 171 patients with
recurrent SCLC were entered into the study from 43 German
centers. The present evaluation is based on 100 patients, for
whom complete data sets were available.
Main patient characteristics are listed in table 1. There were
only 5% of the patients with limited disease, all other patients
were extensive disease. Two thirds of the patients had a plat-
inum-based first-line therapy, one third had mostly CAV or a
modification of CAV as first-line therapy. Refractory patients
was one third, and two thirds of the patients were considered
sensitive with relapses between 3 and 6 months after first-line
therapy. In first-line therapy patients had 23% complete re-
mission (CR), 53% partial remission (PR), 5% stable disease
(SD) and 19% progressive disease (PD).
Dose Intensity
A total of 295 courses was given, the mean dosage was 1.28
mg/m2/day. About 29% of the cycles could be increased to 1.5
mg/m2/day, only 8.3% of the cycles had to be reduced to 1.0
mg/m2/day. The mean dose density was (mg/m2/day of a 21-
day cycle) 0.26 in cycle 1, 0.3 in cycle 3, and 0.27 in cycle 5
(table 2).
Evaluation of Efficacy
The overall response rate was 14%. There were 14 patients
(14%) with partial remission. 40 patients (40%) had stable
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Table 1. Main patient characteristics
n %
Eligible 171
Evaluable 100
Sex
Male 75
Female 25
Age 
Median, years 60
Range, years 38–76
ECOG performance status
0 (Karnofsky 100%) 16 16
1 (Karnofsky 80–90%) 59 59
2 Karnofsky 60–70%) 25 25
Extent of disease at study entry
Limited disease 5 5
Extensive disease I 18 18
Extensive disease II 77 77
Brain metastases present 24 24
First-line therapy
Platinum-based 66 66
Non-platinum-based 34 34
Time to relapse after first-line therapy
< 3 months (refractory) 34 34
≥ 3 months to < 6 months (sensitive) 66 66
Best response to first-line therapy
CR 23
PR 53
SD 5
PD 19
and 46 patients (46%) had progressive disease. We observed
the same partial remission rate in platinum-based and non-
platinum containing first-line therapy. There were little differ-
ences in the percentage of stable and progressive disease cate-
gories between platinum-based and non-platinum containing
first-line therapy, this was also evident for performance status
ECOG 0–1 and ECOG 2 (table 3). In 46% of the 24 patients
with brain metastases, disease was arrested and 54% pro-
gressed. 
The median time to progression for all patients was 8 weeks.
Although there was a statistically significant difference re-
garding time to progression in those patients who could be in-
creased with their dose (14 weeks time to progression), the
median survival was equal. The 14 patients who responded
had a median duration of response of 9 weeks. 
The median survival time of all patients was 25 weeks. There
were no differences between the type of first-line therapy or
sensitive versus refractory. There was a difference in median
survival time between the performance status: 25 weeks
ECOG 0–1, 22 weeks ECOG 2.
Toxicity
The hematological side effects were remarkably rare with
grade 4 neutropenia in 11.5% and thrombocytopenia grade 4
in 4.7% of the courses.
At the dose levels of 1.25 mg/m2/day, there was grade 3 neu-
tropenia in 12% and grade 4 neutropenia in 8%. Concerning
the thrombocytes, there was grade 3 thrombopenia in 7% and
grade 4 thrombopenia in 4%. The toxicities were not in-
creased in those patients who could be increased during the
course of their therapy, but they were lower in the dose levels
of 1.0 mg/m2/day.  There were no statistically significant differ-
ences concerning toxicities between the type of first-line ther-
apy. Hematological toxicities were not cumulative during the
course of the therapy. 
There were few non-hematological side effects (fever: 2 pa-
tients, pancreatitis: 2 patients, dyspnoea, pneumonia, gastritis,
erythema: 1 patient each).
Discussion
Prognosis in terms of response and survival of patients with
recurrent SCLC still remains poor. Among several new drugs
investigated during the last few years topotecan, a water-solu-
ble analogue of camptothecin which acts as an inhibitor of
topoisomerase I, has demonstrated significant activity. A
phase II study conducted by the EORTC reported a 21.7%
overall response (38% among sensitive, 6.4% among refracto-
ry patients) and a median duration of response of 33 weeks
[7]. In that study the dose of topotecan was 1.5 mg/m2/day for
5 consecutive days, every 3 weeks. The remission rate ob-
served in another study with topotecan as a single agent with
1.5 mg/m2/days 1–5 was 19% in sensitive patients and 3% in
patients with refractory response to first-line therapy [8].
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Table 4. Comparison of time to progression and survival in relation to
neutropenia and thrombocytopenia from the German multicenter study
and the von Pawel study
SOABB Von Pawel et al. [9]
Study drug topotecan topotecan CAV
Median time to progression, weeks 8 13 12 
Median survival, weeks 25 25 22 
Neutropenia grade 4 
(% of all courses) 11.5 38 52
Thrombocytopenia grade 4 
(% of all courses) 4.7 10.3 1.5
Table 2a. Mean dosage
Total Cycle

1 2 3 4 5 6
N 295 100 83 44 32 20 16
Mean dosage, 1.28 1.25 1.29 1.33 1.39 1.38 1.39
mg/m2/day
Table 2b. Dose intensity 
Dosage Patients Cycles
 mg/m2/day
n % n %
1.0 13 13 24 8.3
1.25 59 59 180 62.5
1.5 28 28 84 29.2
Table 2c. Dose density
Cycle 

1 2 3 4 5
N 83 44 32 20 16
Dose density mean 0.26 0.29 0.3 0.28 0.27
(mg/m2/day of a 21-day-cycle)
Table 3. Response rates
Response, All Platinum Non- ECOG 0–1 ECOG 2
% patients platinum
(n = 100) (n = 66) (n = 34) (n = 75) (n = 25)
CR 0.0 0.0 0.0 0.0 0.0
PR 14.0 14.0 15.0 12.0 20.0 
SD 40.0 36.0 47.0 40.0 40.0
PD 46.0 50.0 38.0 48.0 40.0
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Perez-Soler et al. [11] already conducted a study with a
topotecan dosage of 1.25 mg/m2/day. They recorded a remis-
sion rate of 11% (only partial remissions), 17% had stable dis-
ease and the median survival was 20 weeks.
Due to the promising results observed in these studies, a ran-
domized phase III trial of topotecan as single agent versus
CAV was performed [9]. In that multicenter trial, a total of
211 evaluable patients were included. As the patient charac-
teristics are very similar to each other, a comparison of both
studies is interesting (table 4). In the German multicenter trial
the response rate achieved so far is 14% partial remission, the
topotecan arm of von Pawel’s study had 24%, the CAV arm
16%. The progression rate was 46% in the German multicen-
ter trial versus 44.5 and 53% in the two arms of von Pawel’s
study. Although there were differences in the median time to
progression (German multicenter study: 8 weeks, topotecan
arm: 13 weeks, CAV arm: 12 weeks), the median survival time
so far is 25 weeks for both topotecan arms, the dose adjust-
ment for each patient in the German multicenter study and
the standard dose of 1.5mg/m2/day in von Pawel’s study, com-
pared to 22 weeks in the CAV arm (fig. 1). 
A comparison of the results regarding survival and myelotoxi-
city is summarized in table 4. 
The topotecan dose modification could reduce myelotoxicity
to half that of the standard treatment.
Thus in the German multicenter study presented here, there
was the same efficacy and survival compared to a combina-
tion of 3 drugs with markedly less toxicity due to the lower
starting dose of topotecan of 1.25 mg/m2/days 1–5 and subse-
quent dose modifications. Therefore topotecan has clearly an
impact on survival in second-line therapy of small-cell lung
cancer.
Appendix
The following institutions participated in this study:
Städtische Klinik Leipzig West, Krankenhaus Großhansdorf, Zentral-
krankenhaus Gauting, Klinikum Schillerhöhe, Gerlingen, St. Vincentius-
Krankenhaus, Karlsruhe, Malteser KRH St. Franziskus-Hospital, Flens-
burg, Clemenshospital, Münster, Fachklinik Kutzenberg, Ebensfeld, Med.
Einrichtungen der Rhein. Friedrich-Wilhelms-Universität, Bonn, Kran-
kenhaus Donaustauf, Klinikum Rechts der Isar, München, Medizinische
Fakultät der Univ. Magdeburg, Diakoniekrankenhaus Halle, Klinikum
der Albert Ludwigs-Universität, Freiburg, Krankenhaus Zschadraß, Zen-
tral-Krankenhaus Bremen Ost, Zentralklinikum Augsburg, Mutterhaus
der Borromäerinnen, Trier, Krankenhaus Nordwest, Frankfurt, Fachkran-
kenhaus Coswig, Klinikum der Hansestadt Stralsund GmbH, Allgem.
Krankenhaus Hamburg-Harburg, Klinikum St. Marien Amberg, Univer-
sitätskliniken des Saarlandes, Homburg-Saar, Fachkrankenhaus für Lun-
gen- und Thoraxchirurgie, Berlin, Krankenhaus Düren, Augusta-Kran-
kenanstalt, Bochum, Kliniken Essen-Mitte , Klinikum Innenstadt, Lud-
wig-Maximilians-Universität, München, Klinikum Neubrandenburg, Kli-
nikum Nürnberg, Krankenhaus der Barmherzigen Brüder, Regensburg,
Städtisches Krankenhaus Bogenhausen, München, Städt. Krankenanstal-
ten Krefeld, Klinikum der J. W. Goethe-Universität, Frankfurt, Univer-
sitätskrankenhaus Eppendorf, Hamburg, Städtisches Krankenhaus Hei-
dehaus, Hannover, Städt. Klinikum Karlsruhe, Klinik Bad Trissel, Obe-
raudorf, Lungenfachklinik Philippstiftung e. V. , Immenhausen, Klinikum
Chemnitz GmbH, Universitätsklinik, Jena, Universität Leipzig, Medizini-
sche Universitätsklinik, Rostock
Fig. 1. Kaplan-Mayer plot for survival of both trials, German multicenter
SOABB and von Pawel’s study.
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